FDA Drug recall D-1337-2022
Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864
- FDA Drug
- Class I
- terminated
- Published 2022-07-27
On 2022-07-27 the FDA classified a Class I recall of Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864 by Loud Muscle Science, citing marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, ma….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1337-2022 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2022-06-27 |
| Published | 2022-07-27 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Loud Muscle Science |
| Distribution | US |
Product
Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864.
Reason
Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Identifiers
| upc | 661020846864 |
|---|---|
| code_info | Lot # 2022104, Exp. Date 04/2025 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1337-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.